Transcatheter technologies transformed the treatment of coronary artery disease. From the first percutaneous balloon angioplasty in 1977, to the first self-expanding stent in 1986 and first drug-eluting stent in 1999, to the biodegradable and bioresorbable stents we have today, many millions of patient lives have been saved and billions in economic value created.
Read MoreTopics: medtech, product portfolios, patient journey, transcatheters, stents
Matt Singer co-wrote this blog post with Sundeep Karnik.
Recently, the FDA announced new steps to modernize its 510(k) regulatory clearance pathway. This is the first major overhaul of a process that has been in place since 1976. The FDA intends to implement three major changes:
Read MoreTopics: product launch, medtech, product portfolios, regulations, FDA, medtech innovation
Medtech has always been known as an innovative industry. Most organizations are primarily focused on the next growth-driving product launch, whether it is an entirely new product category or a simple line extension. While this approach has been immensely successful in the past, many organizations are being forced to rethink their product strategy as the medtech environment changes.
Read MoreTopics: medical devices, Matt Scheitlin, medical products and services, medtech, product portfolios, solutions
Transcatheter technologies transformed the treatment of coronary artery disease. From the first percutaneous balloon angioplasty in 1977, to the first self-expanding stent in 1986 and first drug-eluting stent in 1999, to the biodegradable and bioresorbable stents we have today, many millions of patient lives have been saved and billions in economic value created.
Matt Singer co-wrote this blog post with Sundeep Karnik.
Recently, the FDA announced new steps to modernize its 510(k) regulatory clearance pathway. This is the first major overhaul of a process that has been in place since 1976. The FDA intends to implement three major changes:
Medtech has always been known as an innovative industry. Most organizations are primarily focused on the next growth-driving product launch, whether it is an entirely new product category or a simple line extension. While this approach has been immensely successful in the past, many organizations are being forced to rethink their product strategy as the medtech environment changes.
View All ZS Offices
